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Patients with autoimmune pancreatitis have a striking polyclonal elevation of total IgG4 in serum. This observation has been
conﬁrmedandextendedtootherﬁbroticconditions(thatarethereforecalledIgG4-relateddisease)butasyetremainsunexplained.
The aﬀected tissue contains many IgG4-producing plasma cells embedded in a ﬁbrotic matrix originating from activated
mesenchymal (stellate) cells. We propose that the process results from an unusual interaction between two regulatory systems: the
regulatory arm of the immune system (including Bregs) and the tissue repair regulatory components orchestrated by the activated
stellate cell. This interaction results in ongoing mutual activation, generating TGFbeta, IL10, and vitamin D. This environment
suppresses most immune reactions but stimulates the development of IgG4-producing plasma cells.
1. IgG4Production in IRD
IgG4-related disease (IRD, see Box 1)i sag r o u po fd i s e a s e s
withdisparatesymptoms,butsharingacommonpathophys-
iology, which has only recently been recognized as a new
diseaseentity[1].IRDischaracterizedbymassiveinﬁltration
of the aﬀected organ by IgG4-positive plasma cells. This
inﬁltration coincides with a disruption of the organization
of the tissue and thus of tissue function. The extent of
the plasmacytic tissue reaction in IRD is such that the ﬁrst
impression is often that of a tumor. While the prototypic site
of IgG4 production in IRD is the pancreas, many other sites
inthebodycanbeinvolved,forexample,thesalivaryandtear
glands, reminding of Sj¨ ogren’s syndrome. However, in IRD,
the ducts usually remain largely intact, and secretion by the
glands is less severely aﬀected [2]. It is not at all unusual to
ﬁndseveralorganstobeinvolvedsimultaneously(fordetails,
see Box 1).
A 5–50-time elevation of total IgG4 levels is found in
patients with IRD. This results in a markedly increased
IgG4/IgG ratio, both for serum immunoglobulin levels and
for plasma cells in the aﬀected tissue. It is not clear if the
increased levels of IgG4 contribute to the pathology of IRD.
So far, convincing support for the hypothesis that (auto-)
antibody activity of IgG4 is driving the pathology is lacking.
Several candidate autoantibodies have been suggested in
IRD, such as antibodies directed against pancreatic trypsin
inhibitor, lactoferrin, and carbonic anhydrase, mainly in
patients with pancreatic involvement [3]. These antibodies
were mostly not of the IgG4 subclass. Since they are present
in only a small part of the patients, their role in the
pathophysiology of the disease is probably limited. In the
absence of an obvious (auto) antigen driving the reaction, it
is unclear how these responses are triggered, and, therefore,
how IRD may develop.
Toll-like receptor and Nod-like receptor stimulation have
also been implied in IRD, since PBMCs of IRD patients
produce IL-10 and high levels of IgG4 in response to
stimulation of these receptors in a BAFF-dependent manner
[4, 5].
Recently, some IRD patients have been treated with
Rituximab, a monoclonal antibody drug that targets CD20
[6]. Patients treated with Rituximab show a fast decline in
serum IgG4 levels, while the decrease of other subclasses is
less pronounced [7]. This is not due to a direct eﬀect on the
IgG4-producing plasma cells, because CD20 is present on B2 International Journal of Rheumatology
IgG4-related disease (IRD) is a syndrome characterized by raised serum IgG4 levels. Clinically, tumor-like enlargements are
observed, often in the retroperitoneal area or in one or more exocrine glands, most commonly in the pancreas, biliary tract,
with more submandibular gland and lacrimal gland. The pathology involves a massive polyclonal lymphoplasmacytic
Inﬁltration more than 30% of the plasma cells staining for IgG4, and ﬁbrosis with a typical star-like or storiform appearance.
The lymphocytes are mostly T helper cells, which presumably are follicular Th cells [28], and relatively few B cells.
Furthermore, extensive neutrophil inﬁltration is absent in IRD. Manifestations of IRD are manifold. Descriptions of the
full clinical and pathological spectrum of IRD can be found, for instance, in the reviews by Umehara [1]a n db y
Khosroshahi and Stone [29]. An illustration of the scope of the spectrum is the ﬁnding that IRD is involved in many cases of
retroperitoneal ﬁbrosis, which may cause severe, potentially fatal, aortic pathology, including aortic aneurism [30].
The pancreatic variant of IRD is often referred to as autoimmune pancreatitis (AIP) type 1, which should be distinguished
from the classical duct-destructive AIP, nowadays called AIP type 2 [31]. In AIP type 1, the glandular ducts are typically
not inﬁltrated.
Similarly, if salivary and tear glands are aﬀected, their secretion is less aﬀe c t e dt h a ni nS j¨ ogren’s syndrome,
because the ducts remain relatively undamaged. Extensive neutrophil inﬁltration is absent in IRD. Lymph nodes may be
involved in IRD, raising suspicion of IL-6-hypersecreting multicentric Castleman’s disease (MCD). However, IgG4-RD
cases have been found to be negative for the herps virus associated with MCD, and IgG4-RD is not associated with fever.
The complex connection between IRD and lymphadenopathy is well discussed by Sato et al. [32]. The emphasis in this
opinion is on the pancreas and related tissues (biliary tree, salivary glands, and tear glands). In other locations, some aspects
of the histopathology may diﬀer, particularly the extent of the ﬁbrosis.
Box 1: IgG4-related disease (IRD).
cells from the pre-B cell stage, but is lost upon diﬀerentiation
into plasma cells. Therefore, the rapid decline of IgG4 levels
upon B-cell depletion strongly suggests that the lifespan of
the IgG4-secreting plasma cells is short, that is, less than a
week.ThelargenumberofIgG4-secretingplasmacellsbefore
treatment must be caused by the continuous diﬀerentiation
of IgG4-switched B cells into plasma cells.
Here, we will discuss two features related to IgG4 that
maybeinvolvedinthepreferentialrecruitmentandretention
of IgG4-switched B cells into the aﬀected tissue in IRD. First,
as explained below, IgG4 has been linked to “tolerogenic”
immune responses. Second, there are indications of unusual
Fabglycosylationin(partof)IgG4.Ourhypothesisisthatthe
B-cell receptors (BCRs) of some B cells are Fab glycosylated
with an oligomannose glycan, which is recognized by an
endogenous lectin found on the tissue-resident myoﬁbrob-
last (stellate cell). This interaction may result in an ongoing
mutual stimulation of two regulatory systems: the blood-
derived immune regulators, including IgG4-committed B
cells, and the tissue-resident damage-controlling stellate cell,
resulting in the pathology observed in IRD.
2.IgG4:An AntibodyLinkedto
Tolerogenic Conditions
IgG4 is a peculiar subclass of human immunoglobulins.
It represents about 5% of total IgG in serum of healthy
adults (0.5g/L, normal range: 0.05–1.4g/L). However, IgG4
antibody can represent up to 80% of total IgG antibody after
chronic exposure to antigen [8, 9]. Since IgG4 antibodies do
not activate complement and bind to Fc receptors with lower
aﬃnity [10], they do not activate the eﬀector functions of
the immune system in the same way the other subclasses do
[11, 12]. Furthermore, IgG4 antibodies are able to exchange
half molecules in vivo [12, 13]. This process results in the
generation of asymmetric antibodies with two diﬀerent Fab
arms. Since these antibodies can, in general, only bind to
antigen with one Fab arm, IgG4 is not able to cross-link
antigens and thus to form large immune complexes. IgG4
has even been shown to interfere with the complement-
activating and immune-precipitating activities of human
IgG1 antibodies [14].
All in all, the immunochemical properties of IgG4
antibodies point towards a dampening role in the eﬀector
phase of the immune response. This ﬁts well with the
requirements for IgG4 production. IgG4 responses require
frequent and/or high antigen exposure and are observed in
situations associated with tolerance induction, such as dur-
ing immunotherapy. IgG4 responses are also often associated
with IgE-mediated allergy, but IgG4 responses are distinct
from IgE responses. Although both IgG4 and IgE need the
Th2 cytokines IL-4 and/or IL-13 [15], production of IgE
antibodies often occurs well before IgG4 antibodies appear
(e.g., in novice beekeepers [8]). It is also common to ﬁnd
IgG4 antibodies in the absence of IgE antibodies, a process
called the modiﬁed Th2 response [16]. One important
regulatory component in the modiﬁed Th2 response is IL-
10. Under the inﬂuence of this cytokine, the switch to IgE is
inhibited, while switch to IgG4 is promoted [17].
In the case of prolonged and/or high-dose antigenic
stimulation, immune regulatory circuits play an important
role. They counteract the eﬀects of antigenic stimulation and
dampen the immune response, resulting in, amongst others,
the decrease of Teﬀector responses and of the production
of human IgG1 antibodies. It is only then that the IgG4
response develops to its full extent. One of these regulatory
signals is the above-mentioned cytokine IL-10. This explains
why upon chronic exposure to antigen, IgG4 levels increase.
It is likely that IL-10 needed for the development of an
IgG4 immune response is in part produced by Tregs present
in the lesions of IRD patients as demonstrated by in situInternational Journal of Rheumatology 3
Fibrosis is a reaction of a ﬁbroblast to injury. Upon activation, the ﬁbroblast becomes a myoﬁbroblast,
which produces (intracellular) myosin and starts secreting matrix proteins, particularly collagens [33].
This local ﬁbrotic damage control program is often accompanied by an inﬂammatory reaction [34].
The inﬂammation generates an inﬂux of external “damage controllers,” including granulocytes, monocytes, lymphocytes,
and the recently recognized monocyte-related ﬁbrocyte [35, 36]. Depending on the nature and the time course of the damage
the cellular composition of the inﬁltrate will vary markedly, which results in a broad spectrum of tissue changes.
Macrophages are assumed to play a crucial role in the regulation of inﬂammation and ﬁbrosis [37].
In IgG4-related ﬁbrosis, the contribution of neutrophils is typically small.
In the pancreas, the cell most prominently involved in ﬁbrotic reactions is often referred to as “spindle cell,”
which is not a well-deﬁned (myo-) ﬁbroblast cell type. In 1998, a ﬁbroblast-related cell with all characteristics of
the hepatic stellate cell was identiﬁed in the pancreas [38]. The stellate cell is also known as “lipocyte,”
because of the presence of many lipid-containing vesicles that show a typical autoﬂuorescence caused
by the presence of vitamin A [39]. The presence of these lipid vesicles results in a characteristic low buoyant density, which can
be used to isolate stellate cells. Hepatic stellate cells have been found to be closely associated with plasma cells in hepatic ﬁbrosis
[40]. Upon activation, the stellate cell releases much of its lipid vesicles, which makes it more diﬃcult to distinguish it
from other myoﬁbroblast-related cells. For a recent review on the pancreatic stellate cell, see [41].
In IgG4-related ﬁbrosis, the characteristic pattern is described as “storiform,” a whirling pattern.
This pattern presumably reﬂects the interaction of clusters of proliferating myoﬁbroblasts [42].
One of the functions of myoﬁbroblasts is to contract during a wound
healing process. Such a contraction in the absence of a wound to heal may result in a whirling pattern. Plasma cells
(of which typically more than 40% are IgG4 producing) are found within this ﬁbrotic network, suggesting that this could be
a niche for the IgG4 plasma cells in IRD.
Box 2: The role of the myoﬁbroblast-type stellate cell in ﬁbrosis, tissue repair and plasma cell diﬀerentiation.
hybridization [18], as well as increased levels of circulating
Tregs [19]. Besides Tregs, another likely source for IL-10 is
regulatory B cells (for a review on regulatory B cells, see
[20]), some of which may later develop into IgG4-producing
cells [21].
3. IgG4FabGlycosylation
There are indications that IgG4 may sometimes be unusually
glycosylated in the Fab region: two sets of information
point to a link between IgG4 and Fab glycosylation of
the oligomannose type. First, a subject that has been
studied for many years by Margni and coworkers is the
association between oligomannose-type Fab glycosylation
and nonprecipitating antibodies. They fractionated antigen-
speciﬁc polyclonal antibodies based on their glycosylation
patternbyConAlectinchromatography,whichpreferentially
binds oligomannose glycans. The bound fraction was unable
to form an immune precipitate with antigen. The lack of
immune precipitation was found to be due to asymmetric
Fab glycosylation, that is, glycosylation of only one of
the two antigen-binding domains. A possible mechanism
explaining the formation of asymmetrically glycosylated
antibodies is the aforementioned Fab arm exchange of IgG4.
Fab arm exchange between glycosylated and nonglycosylated
IgG4 would result in a nonprecipitating asymmetrically
glycosylated antibody. Conditions that lead to enhanced
production of asymmetrically glycosylated antibody (such
as pregnancy) are similar to the tolerizing conditions that
promote IgG4 production. These data suggest that IgG4
might be preferentially Fabglycosylated with oligomannose
glycans.
The othersetof informationcomes fromastudy on IgG4
antibody responses in infancy to a panel of food allergens
[22] .I nt h i ss t u d y ,as t r o n gr e a c t i v i t yt oap r o t e i ni nb a n a n a
was found, which was then characterized and found to be a
lectin with a preference for oligomannose glycans: BanLec1
[23, 24]. IgG, including IgG4, is a glycoprotein. The obvious
question was whether BanLec1 bound to a glycan on IgG4,
orwhetherIgG4reactedasagenuineantibodywithaprotein
that happened to be a lectin. At that time, IgG glycosylation
was generally assumed to be restricted to the Fc part and
was of the complex glycan type. When we found that the
binding of BanLec1 to IgG4 was restricted to the Fab part,
we considered this to be a strong argument in favor of
IgG4 binding as an antibody, rather than as a glycoprotein.
However, these recent data make us uncertain about the
interpretation of our earlier results, and research is currently
carried out to further explore the glycosylation of IgG4.
4. Lectin-DrivenB-Cell Activation
As already mentioned, because of the highly elevated levels
of IgG4 in serum of IRD patients (typically more than 5g/L),
we consider it unlikely that the signal for activation of the
IgG4+ B cell is a regular antigen. The above-mentioned
indications of unusual glycosylation of the Fab of (part
of) IgG4 suggest that, instead, an endogenous lectin may
function as an alternative trigger of the BCR. The B cell
would be activated by the lectin upon cross-linking of the
BCR via its Fab glycan. In a way, the lectin would act as an
endogenous superantigen, resulting in recruitment of IgG4-
switched B cells in particular.
Support for an “oligomannose Fab glycan + endogenous
lectin” scenario for IRD comes from the work of Stevenson4 International Journal of Rheumatology
A hallmark of IRD is a substantially elevated serum level of IgG4, even if in some patients the level is in the normal range. The
ﬁnding of large numbers of IgG4-positive plasma cells in the aﬀected organ, makes it likely that this is the primary source of
the increased IgG4 production. Yet, we want to address the quantitative aspect: does the histological analysis show a suﬃcient
number of plasma cells to explain the IgG4 level in the serum? As detailed below, there may be cases where additional sites of
IgG4 production are likely to be present. The following calculation depends on three estimates: (1) the daily production rate
needed to maintain the IgG4 level in plasma, (2) the number of plasma cells in the aﬀected organ and (3) the
IgG4 production per plasma cell.
(1) The daily production rate of IgG for a 70kg healthy adult is 2g, which maintains a plasma level of 12g/L (1200mg/dL).
The IgG4 level in IRD is on average 3g/L, which is 2.6g/L higher than the average normal level (0.4g/L).
Assuming a similar turnover, the increased IgG4 level requires a daily production of 2 ×2.6/12 = 0.43 gram
“pathological” IgG4.
(2) The number of plasma cells (PCs) in the aﬀected organ is not known, but an estimate can be made. In high-density
areas of aﬀected tissue, 100 IgG4+ PCs per HPF (of 0.2mm2) is considered convincingly positive. This corresponds to
500PCs/mm2. Assuming a section thickness of 4μm, this would correspond to a cell density of 125000PCs/mm3.
However, the same PC (average diameter 12μm) will be visible in 3 to 4 consecutive sections, so the actual density
will be 37000PCs/mm3,o r3 7m i l l i o nP C s / c m 3 tissue. Since the PCs are usually counted in areas selected for high
PC numbers, this is likely to be an upper limit of the number of plasma cells per gram aﬀected tissue.
(3) Ig production per PC has been estimated both from in vitro and from in vivo data. In vitro, a production rate
of 1000pg/PC/24hrs has been reported [43], much higher than in vivo. The number of PCs in bone marrow,
spleen, and mesenteric and inguinal lymph nodes (so, without the mucosal plasma cells and contributions of scattered
plasma cells found all over the body) has been reported to be 25 ×109 [44], of which some 60% (15 ×109)p r o d u c e
IgG [45]. This would indicate a daily production rate of 2000 ×109 pg IgG/15 × 109 PCs, or 133pg/PC/24hrs.
(4) Combining the in vivo production rate with the plasma cell numbers, a tissue mass of 1 gram (containing 37 ×106 PCs)
would produce 133 ×37 ×106 = 5 ×109 pg = 5mg IgG4/day, which is 1.2% of the amount required to maintain an
IgG4 level in plasma of 2.6mg/mL, and the average level of “pathological” IgG4 is serum. This corresponds to 86 gram
IgG4-rich tissue. Using the 7.5 times higher daily production rate derived from cultured cells, the value is 12 gram.
For a pancreas, which in pathological conditions may well be over 100 gram, the calculated required mass may seem to
correspond reasonably well, considering that these calculations are based on imprecise estimates. However, the actual number
of plasma cells in the aﬀected organ is likely to be substantially lower than the number calculated from the counts in areas with
high plasma cell density (which are the areas selected during the evaluation of the histological sections). Furthermore,
IgG4 levels in some of the IRD patients are substantially higher than 3g/L. Particularly in the latter patients, it is relevant to
note that the IgG half-life shortens at high IgG levels. This obviously increases the number of plasma cells required. It is clear
that we need better data, particularly on the number of IgG4 PC in a total aﬀected tissue. Still, our calculations suggest that in
some Patients, other tissue sources, without obvious pathology, might be important contributors to IgG4 production in IRD.
Box 3: A quantitative conundrum: the number of tissue-residing plasma cells is insuﬃcient to explain the strongly elevated IgG4 level in
plasma.
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Figure 1: Proposed model of B-cell inﬁltration into aﬀected tissue. (a) B cells from the circulation enter the inﬂamed tissue. (b) Diﬀerential
glycosylation of IgG4-switched B cells allows retention and activation of this cell type via an as-yet-unidentiﬁed lectin on the stellate cell.
(c) In this model, the local environment of the aﬀected tissue will further promote survival/proliferation of IgG4-switched B cells due to a
tolerogenic environment that may in part be created via signals from the IgG4 B cells themselves.International Journal of Rheumatology 5
and coworkers on the activation of B cells in follicular lym-
phoma(FL).TheyfoundthatthemajorityofFLcasesinvolve
amutationresultingintheincorporationofaglycanacceptor
site in the variable region of the Ig [25]. They showed
that the binding of mannose-binding lectin to the FL cells
triggers BCR-mediated signaling. These cells do not need
to recognize antigen anymore to proliferate, giving them a
major growth advantage. Furthermore, they found that the
glycan attached to the Fab arm in these follicular lymphomas
is terminated in oligomannose, an uncommon structure
for human glycoproteins. Interestingly, cases of IRD are
sometimes mistaken for FL due to similarities between
these two diseases. In both IRD and FL, B-lymphocytes
invade tissues and extensively proliferate there. However, in
IRD the cells diﬀerentiate into plasma cells, whereas in FL
they typically do not, making high serum levels of IgG4
a diagnostic marker to distinguish IRD from lymphoma.
Furthermore, the IgG4 cells in IRD are of polyclonal origin,
in contrast to the monoclonal B cells in FL.
5. A Model for IgG4 Plasma Cell
Development inIRD
Based on the requirements for IgG4 production and the link
between IgG4 and Fab oligomannose glycans, we propose
a model in which B cells in circulation are entering into
the inﬂamed tissue, where IgG4 cells are preferentially
retained and diﬀerentiate in the tolerogenic environment of
the lesion (Figure 1). The initial sequence is presumably a
traumatic or infectious event that triggers a repair response.
In case of pancreatitis, the local repair reaction in the
tissue is orchestrated by the pancreatic stellate cell (see
Box 2), which results in a storiform ﬁbrotic reaction, one
of the hallmarks of IRD. This results in the attraction and
entrapment of circulating regulatory cells, including Tregs
and Bregs, together creating a “tolerogenic” environment
characterized amongst others by cytokines like IL-10 and
IL-21, as well as vitamins A and/or D released from the
activated stellate cells. In this environment, interaction of
inﬁltrated IgG4-switched B cells with an as-yet-unidentiﬁed-
lectin in combination with the tolerogenic conditions leads
to diﬀerentiation of these B cells to plasma cells (but also
see Box 3). On the other hand, proliferation/diﬀerentiation
of other B cells is disfavored. Support in favor of this scheme
comes from the IgG4 plasmacytosis seen in myoﬁbroblastic
tumors [26, 27]. This repair process should be self-limiting,
but somehow this feedback is not working, and a feed-
forward reaction is initiated. To stop this feed-forward loop,
not only the B cells but also the stellate cells may need to
receive signals to terminate their “repair mode” that sustains
thelocaltolerogenicconditions.Thiscouldexplainwhyanti-
CD20 B cell depletion therapy with Rituximab needs to be
perpetuated: it targets the B cells but leaves the pancreatic
stellate cell unaﬀected. How can we regulate the regulators?
6.Perspectives
Some of the many questions that need to be answered are the
following: (1) upon stimulation, is the stellate cell capable
to initiate or increase the production of the hypothetical
oligomannose-speciﬁc lectin, and of chemokine receptor
ligands that attract Tfh and class-switched B cells? Possible
involvement of BCR stimulation via oligomannose could be
studied in vitro, for example, using BanLec-1, something
that is currently being pursued in our lab; (2) what is the
phenotype of the T cells (e.g., Tfh or Treg) and B cells (e.g.,
IL-10 producing and/or IgG4 switched; glycosylation status
of BCR) within the aﬀected organ?; (3) what is the relation
betweenthelymphocytesinthetissueandthoseintheblood,
particularly in relation to their chemokine receptors and (for
the B cells) their Fab glycosylation proﬁle?
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